

UBI signs Henry Schein as first distribution partner for Xprecia Prime in USA

Universal Biosensors, Inc. (ASX: UBI) is pleased to announce it has signed Henry Schein, Inc. as its first major distribution partner in the United States of America.

Henry Schein is one of the USA's largest and most influential distributors of medical products and is a leader in the distribution of coagulation products in the USA.

The deal is for Henry Schein to become a non-exclusive distributor for an initial term of 1 year, with annual extensions by agreement.

Mr John Sharman CEO of UBI said, "Henry Schein undertook a comprehensive product review before agreeing to partner Xprecia Prime. Henry Schein service thousands of coagulation clinics and hospitals throughout the USA which can now access Xprecia Prime through the Henry Schein network. First sales are expected in the coming weeks."

Mr Sharman said, "Over recent months we have recruited key staff to build our USA Xprecia business. We continue to negotiate additional distribution deals for Xprecia in the USA and we look forward to reporting our progress."

End

Announcement authorised by the Board of Directors of Universal Biosensors, Inc.

For further information contact:

John Sharman
Chief Executive Officer
+61 (0) 414 440 680

About Universal Biosensors

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), wine, food, and agriculture. UBI's ambition is to build a multi product stable of biosensors in large markets which generate ongoing revenue streams. For additional information regarding Universal Biosensors, Inc., refer to: <http://www.universalbiosensors.com>.

About Xprecia Prime™

The Xprecia Prime™ Coagulation Analyzer is Universal Biosensors second generation, new and improved coagulation monitoring device. Xprecia Prime™ fits into your palm; is portable, accurate and easy to use. The device is designed for fast and reliable prothrombin time (PT) results displayed in seconds and International Normalised Ratio (INR). It is used to monitor the dosage of vitamin K antagonists in patients to ensure its safety and efficacy. Dangerous bleeding events can occur if the ideal dosage of the drug is exceeded, while if the dosage is lower than required the patient is at risk of thrombosis. The prothrombin time (PT) test allows physicians to appropriately adjust the patient's dose of the drug to compensate for any diet and lifestyle changes. Globally, approximately 10 million patients are taking warfarin, and over 300 million PT/INR tests are conducted annually to monitor the safe and effective dosage of anticoagulants, representing a major market opportunity for Xprecia Prime™. For additional information visit: <https://www.universalbiosensors.com/products/xprecia/>

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.